Welcome to our dedicated page for Burning Rock Biotech news (Ticker: BNR), a resource for investors and traders seeking the latest updates and insights on Burning Rock Biotech stock.
News coverage of Burning Rock Biotech focuses on regulatory approvals, clinical validation studies, pharmaceutical partnerships, and financial performance. Significant attention centers on the company's progress in advancing cancer early detection technologies through clinical trials and regulatory review processes. Media reports frequently highlight new companion diagnostic approvals that enable the company's tests to guide treatment decisions for specific cancer therapies.
Quarterly earnings announcements generate coverage analyzing revenue trends across the company's business segments, including clinical testing services and pharmaceutical research partnerships. Financial media examines metrics such as test volume growth, gross margins, operating expense management, and the path toward profitability. Analyst commentary often evaluates the company's competitive positioning within the molecular diagnostics industry and growth prospects in different geographic markets.
Partnership announcements with pharmaceutical companies, medical device manufacturers, and healthcare systems receive coverage as indicators of commercial validation and market expansion. News about new laboratory accreditations, expanded test menu offerings, and entry into additional countries signals operational development. Scientific presentations at oncology conferences and publication of clinical validation data in peer-reviewed journals demonstrate progress in building evidence for the company's diagnostic platforms.
Regulatory milestones such as breakthrough device designations, in vitro diagnostic approvals, and companion diagnostic clearances represent major news events that can impact market access and revenue potential. Coverage also tracks developments in the broader precision oncology field, including competing technologies, reimbursement policy changes, and evolving clinical guidelines that may affect adoption of genomic testing. Stock performance, analyst ratings, institutional investment activity, and corporate governance matters round out the news landscape for Burning Rock Biotech.
Burning Rock Biotech (NASDAQ: BNR) reported Q2 2021 revenues of RMB127.3 million (US$19.7 million), a 19.0% increase year-over-year. The company is focused on early cancer detection technology and plans to commercialize its 6-cancer early detection product in 2022, with contracts signing at six hospitals underway. However, operating expenses surged 93% to RMB292.3 million (US$45.3 million), leading to a net loss of RMB203.7 million (US$31.5 million). The company adjusted its 2021 revenue guidance to approximately RMB500 million, reflecting challenges from COVID-related testing impacts.
Burning Rock Biotech Limited (NASDAQ: BNR) has partnered with IMPACT Therapeutics to advance companion diagnostics (CDx) for the PARP inhibitor Senaparib, targeting prostate cancer. The partnership aims for global CDx submissions to the FDA and NMPA, leveraging Burning Rock's accredited labs in China and California. Senaparib is currently undergoing multiple clinical trials, including a Phase III trial for metastatic castration-resistant prostate cancer (mCRPC). This collaboration is expected to expedite clinical research, benefiting patients worldwide.
Burning Rock Biotech Limited (NASDAQ: BNR) will release its unaudited financial results for Q2 2021 on August 31, 2021, before the U.S. market opens. A conference call will follow at 8:00 a.m. ET to discuss the results. The company specializes in next-generation sequencing (NGS) technology for precision oncology, having completed over 273,000 tests. Burning Rock's focus includes NGS-based therapy selection and cancer early detection, which is in the clinical validation stage. Investors can access earnings results on their investor relations website.
Burning Rock Biotech (NASDAQ: BNR) reported Q1 2021 revenues of RMB106.6 million (US$16.3 million), up 58.4% from Q1 2020, but down 19.1% sequentially due to COVID-19 and seasonal impacts. Their central laboratory revenue rose 61.6% to RMB74.6 million (US$11.4 million), driven by a 64.9% increase in patient tests. However, net loss expanded to RMB171.4 million (US$26.2 million) from RMB52.6 million in Q1 2020. The company forecasts 2021 revenues at approximately RMB610 million (US$93.1 million), indicating 41.9% growth from 2020.
Burning Rock Biotech Limited (NASDAQ: BNR) has launched the PRESCIENT study, the first blood-based pan-cancer early-detection initiative in China using a multi-omics approach. This groundbreaking study will enroll 11,879 participants across 22 cancer types. The project aims to enhance the efficiency of cancer detection through liquid biopsy, promising improved patient outcomes. The study is backed by prominent experts from the National Cancer Center, who emphasize the necessity of advancing early detection technology in China to address rising cancer incidence and to provide clinical evidence for effective diagnostic tools.
Burning Rock Biotech Limited (NASDAQ: BNR) has announced its inclusion in the MSCI China Index effective May 27, 2021. This recognition positions Burning Rock as the only NGS-based precision oncology company from China included in the current MSCI semi-annual index review. The company's mission emphasizes the use of next generation sequencing technology to enhance precision oncology, with significant activities in therapy selection testing and cancer early detection.
Burning Rock Biotech Limited (NASDAQ: BNR) announced a partnership with Abbisko Therapeutics to develop a companion diagnostic (CDx) assay for ABSK091, aimed at detecting FGFR genetic alterations in urothelial carcinoma patients. Prior studies indicated that ABSK091, an FGFR inhibitor, exhibited safety and preliminary efficacy. Abbisko has received IND approval for ABSK091 from the NMPA and plans to initiate phase Ib/II clinical trials in China. This collaboration aims to leverage next-generation sequencing technology to enhance oncology drug development.
Burning Rock Biotech Limited (NASDAQ: BNR) is set to release its unaudited financial results for Q1 2021 on May 25, 2021, before U.S. market opens. The company will hold a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) the same day to discuss these results. Burning Rock focuses on next generation sequencing (NGS) technology in precision oncology, leading the market in China with over 273,000 completed tests. More details will be available on their investor relations website.
Burning Rock Biotech (NASDAQ: BNR) announced strong results from its liquid biopsy assay, recognized in the FDA-led SEQC2 study published in Nature Biotechnology. The assay achieved superior accuracy, sensitivity, and the lowest false-positive rate among five industry-leading ctDNA assays, highlighting its potential in cancer monitoring. With a sensitivity above 90% at low variant allele frequencies (0.3-0.5%), Burning Rock aims to enhance precision oncology solutions. The assay's high performance positions the company favorably within the rapidly evolving NGS-based ctDNA testing market.
Burning Rock Biotech Limited (NASDAQ: BNR) reported its financial results for Q4 and full year 2020, highlighting a 48.5% revenue increase to RMB131.7 million (US$20.2 million) despite COVID-19 impacts. Full year revenues reached RMB429.9 million (US$65.9 million), a 12.6% rise from 2019. The central laboratory business grew by 22.5% year-over-year. However, the company reported a net loss of RMB156.5 million (US$24.0 million) for Q4 and a total loss of RMB407.2 million (US$62.4 million) for 2020. For 2021, Burning Rock anticipates revenues of approximately RMB610 million (US$93.5 million), indicating 41.9% growth.
FAQ
What is the current stock price of Burning Rock Biotech (BNR)?
What is the market cap of Burning Rock Biotech (BNR)?
